STOK
Stoke Therapeutics·NASDAQ
--
--(--)
--
--(--)
STOK fundamentals
During Q4 2025, Stoke Therapeutics (STOK) reported revenue of 1.40M, a YoY change of -93.80%. Net income was -57.93M, a YoY change of -452.70%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2018 | Q2,2018 | Q3,2018 | Q4,2018 | Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2018 | Apr 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2018 | Jun 30, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Dec 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 3.00M -- | 3.23M -- | 2.90M -- | 3.27M -- | 5.15M +71.73% | -2.48M -176.79% | 3.31M +13.87% | 2.80M -14.26% | 4.22M -18.17% | 4.83M +294.72% | 4.89M +47.94% | 22.61M +707.07% | 158.57M +3661.12% | 13.82M +186.01% | 10.63M +117.25% | 1.40M -93.80% | 184.42M -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 3.00M -- | 3.23M -- | 2.90M -- | 3.27M -- | 5.15M +71.73% | -2.48M -176.79% | 3.31M +13.87% | 2.80M -14.26% | 4.22M -18.17% | 4.83M +294.72% | 4.89M +47.94% | 22.61M +707.07% | 158.57M +3661.12% | 13.82M +186.01% | 10.63M +117.25% | 1.40M -93.80% | 184.42M -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.00M -- | 3.23M -- | 2.90M -- | -9.14M -- | 5.15M +71.73% | -2.48M -176.79% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 1.91M -- | 3.01M -- | 3.32M -- | 4.54M -- | 6.32M +230.65% | 8.45M +180.56% | 9.84M +196.71% | 11.07M +143.68% | 11.73M +85.62% | 13.01M +54.08% | 13.71M +39.31% | 14.59M +31.79% | 16.83M +43.39% | 22.03M +69.30% | 22.68M +65.44% | 24.53M +68.15% | 27.80M +65.18% | 28.47M +29.23% | 30.05M +32.49% | 30.44M +24.13% | 29.84M +7.36% | 30.78M +8.12% | 30.54M +1.63% | 32.39M +6.39% | 32.59M +9.20% | 34.17M +11.02% | 34.90M +14.26% | 36.27M +11.98% | 47.33M +45.23% | 41.12M +20.32% | 53.72M +53.95% | 62.84M +73.27% | 205.01M -- |
Selling, General and Administrative Expenses | 660.00K -- | 1.12M -- | 1.09M -- | 1.54M -- | 2.19M +231.67% | 2.42M +115.86% | 3.32M +204.95% | 3.98M +158.71% | 4.52M +106.49% | 5.04M +108.26% | 5.60M +68.53% | 5.68M +42.80% | 6.91M +52.96% | 7.93M +57.30% | 8.32M +48.61% | 8.72M +53.54% | 9.49M +37.20% | 10.11M +27.44% | 9.94M +19.45% | 9.38M +7.57% | 10.21M +7.64% | 10.23M +1.18% | 10.27M +3.29% | 10.61M +13.06% | 10.22M +0.09% | 13.04M +27.44% | 12.69M +23.57% | 12.84M +21.06% | 14.65M +43.38% | 15.26M +17.07% | 16.03M +26.28% | 21.15M +64.64% | 67.09M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 4.41M -- | -- -- | -- -- | -- -- | 11.91M +170.16% | -- -- | -- -- | -- -- | 20.85M +74.98% | -- -- | -- -- | -- -- | 31.90M +53.01% | -- -- | -- -- | -- -- | 38.92M +22.03% | -- -- | -- -- | 10.27M -- | 10.61M -72.74% | 10.22M -- | 13.04M -- | -- -- | 48.79M +359.89% | 14.65M +43.38% | 15.26M +17.07% | -- -- | 67.09M +37.49% | -- -- |
Research and Development Expenses | 1.25M -- | 1.89M -- | 2.23M -- | 3.00M -- | 4.13M +230.11% | 6.02M +219.01% | 6.52M +192.68% | 7.09M +135.99% | 7.21M +74.57% | 7.97M +32.29% | 8.11M +24.41% | 8.90M +25.60% | 9.91M +37.39% | 14.10M +76.90% | 14.36M +77.06% | 15.80M +77.47% | 18.31M +84.70% | 18.36M +30.24% | 20.11M +40.05% | 21.06M +33.27% | 19.63M +7.22% | 20.55M +11.95% | 20.27M +0.81% | 21.78M +3.41% | 22.37M +13.94% | 21.14M +2.85% | 22.20M +9.54% | 23.42M +7.55% | 32.68M +46.08% | 25.86M +22.33% | 37.70M +69.76% | 41.70M +78.01% | 137.92M -- |
Operating Income | -1.91M -- | -3.01M -- | -3.32M -- | -4.54M -- | -6.32M -230.65% | -8.45M -180.56% | -9.84M -196.71% | -11.07M -143.68% | -11.73M -85.62% | -13.01M -54.08% | -13.71M -39.31% | -14.59M -31.79% | -16.83M -43.39% | -22.03M -69.30% | -22.68M -65.44% | -24.53M -68.15% | -24.80M -47.35% | -25.24M -14.57% | -27.15M -19.68% | -27.18M -10.80% | -24.69M +0.42% | -33.26M -31.79% | -27.23M -0.32% | -29.59M -8.87% | -28.37M -14.91% | -29.34M +11.79% | -30.00M -10.17% | -13.65M +53.85% | 111.24M +492.08% | -27.30M +6.96% | -43.09M -43.62% | -61.44M -350.00% | -20.59M -- |
Non-Operating Income (Loss) | -- -- | -- -- | -- -- | 260.00K -- | 580.00K -- | 626.00K -- | 1.24M -- | 908.00K +249.23% | 696.00K +20.00% | 53.00K -91.53% | 27.00K -97.82% | 25.00K -97.25% | 34.00K -95.11% | 62.00K +16.98% | 86.00K +218.52% | 78.00K +212.00% | 146.00K +329.41% | 586.00K +845.16% | 1.04M +1105.81% | 1.52M +1850.00% | 2.15M +1369.18% | 2.61M +345.05% | 2.69M +159.59% | 2.63M +72.78% | 2.00M -6.85% | 3.65M +39.84% | 3.57M +32.73% | 3.17M +20.66% | 2.92M +46.00% | 3.82M +4.66% | 3.47M -2.99% | 3.50M +10.53% | 13.71M -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -10.00K -- | -- -- | -3.00K -- | 2.00K -- | 4.00K +140.00% | 22.00K -- | 14.00K +566.67% | 28.00K +1300.00% | 28.00K +600.00% | 28.00K +27.27% | 28.00K +100.00% | 42.00K +50.00% | 42.00K +50.00% | 42.00K +50.00% | 42.00K +50.00% | 42.00K -- | 42.00K -- | 42.00K -- | 41.00K -2.38% | 41.00K -2.38% | 41.00K -2.38% | -428.00K -1119.05% | -48.00K -217.07% | 28.00K -31.71% | 201.00K +390.24% | 28.00K +106.54% | 28.00K +158.33% | 3.00K -89.29% | -110.00K -154.73% | -51.00K -- |
Net Interest Expense | -- -- | -- -- | -- -- | -270.00K -- | -580.00K -- | -629.00K -- | -1.24M -- | -904.00K -234.81% | -674.00K -16.21% | -39.00K +93.80% | 1.00K +100.08% | 3.00K +100.33% | -6.00K +99.11% | -34.00K +12.82% | -44.00K -4500.00% | -36.00K -1300.00% | -104.00K -1633.33% | -544.00K -1500.00% | -995.00K -2161.36% | -1.48M -4008.33% | -2.10M -1922.12% | -2.57M -371.88% | -2.65M -166.43% | -2.59M -74.92% | -2.43M -15.36% | -3.69M -43.94% | -3.54M -33.72% | -2.97M -14.80% | -2.89M -19.08% | -3.79M -2.54% | -3.46M +2.31% | -3.62M -21.72% | -13.76M -- |
Interest Income | -- -- | -- -- | -- -- | 270.00K -- | 580.00K -- | 629.00K -- | 1.24M -- | 904.00K +234.81% | 674.00K +16.21% | -- -- | -- -- | 700.00K -22.57% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -1.91M -- | -3.01M -- | -3.32M -- | -4.28M -- | -5.74M -200.31% | -7.82M -159.77% | -8.60M -159.39% | -10.16M -137.27% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -43.32% | -16.79M -52.12% | -21.97M -69.51% | -22.60M -65.13% | -24.45M -67.90% | -24.65M -46.78% | -24.65M -12.22% | -26.11M -15.55% | -25.66M -4.94% | -22.55M +8.54% | -30.65M -24.35% | -24.54M +6.01% | -26.96M -5.08% | -26.37M -16.98% | -25.70M +16.18% | -26.43M -7.69% | -10.48M +61.12% | 114.16M +532.84% | -23.48M +8.61% | -39.63M -49.92% | -57.93M -452.70% | -6.88M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 1.28M -- | -- -- | -1.28M -- | -- -- | -- -- |
Net Income | -1.91M -- | -3.01M -- | -3.32M -- | -4.28M -- | -5.74M -200.31% | -7.82M -159.77% | -8.60M -159.39% | -10.16M -137.27% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -43.32% | -16.79M -52.12% | -21.97M -69.51% | -22.60M -65.13% | -24.45M -67.90% | -24.65M -46.78% | -24.65M -12.22% | -26.11M -15.55% | -25.66M -4.94% | -22.55M +8.54% | -30.65M -24.35% | -24.54M +6.01% | -26.96M -5.08% | -26.37M -16.98% | -25.70M +16.18% | -26.43M -7.69% | -10.48M +61.12% | 112.88M +527.99% | -23.48M +8.61% | -38.35M -45.09% | -57.93M -452.70% | -6.88M -- |
Net Income Attributable to Owners of the Company | -1.91M -- | -3.01M -- | -3.32M -- | -4.28M -- | -5.74M -200.31% | -7.82M -159.77% | -8.60M -159.39% | -10.16M -137.27% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -43.32% | -16.79M -52.12% | -21.97M -69.51% | -22.60M -65.13% | -24.45M -67.90% | -24.65M -46.78% | -24.65M -12.22% | -26.11M -15.55% | -25.66M -4.94% | -22.55M +8.54% | -30.65M -24.35% | -24.54M +6.01% | -26.96M -5.08% | -26.37M -16.98% | -25.70M +16.18% | -26.43M -7.69% | -10.48M +61.12% | 112.88M +527.99% | -23.48M +8.61% | -38.35M -45.09% | -57.93M -452.70% | -6.88M -- |
Net Income Attributable to Common Stockholders | -1.91M -- | -3.01M -- | -3.32M -- | -4.28M -- | -5.74M -200.31% | -7.82M -159.77% | -8.60M -159.39% | -10.16M -137.27% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -43.32% | -16.79M -52.12% | -21.97M -69.51% | -22.60M -65.13% | -24.45M -67.90% | -24.65M -46.78% | -24.65M -12.22% | -26.11M -15.55% | -25.66M -4.94% | -22.55M +8.54% | -30.65M -24.35% | -24.54M +6.01% | -26.96M -5.08% | -26.37M -16.98% | -25.70M +16.18% | -26.43M -7.69% | -10.48M +61.12% | 112.88M +527.99% | -23.48M +8.61% | -38.35M -45.09% | -57.93M -452.70% | -6.88M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -42.00K -- | 20.00K -- | -146.00K -- | -516.00K -- | -592.00K -1309.52% | -427.00K -2235.00% | 528.00K +461.64% | 577.00K +211.82% | 219.00K +136.99% | 232.00K +154.33% | 123.00K -76.70% | 24.00K -95.84% | -15.00K -106.85% | 181.00K -21.98% | -317.00K -357.72% | 47.00K +95.83% | 200.00K +1433.33% | 350.00K +93.37% | 97.00K +130.60% | 694.00K -- |
Total Comprehensive Income | -- -- | -3.01M -- | -3.32M -- | -4.28M -- | -5.74M -- | -7.82M -159.77% | -8.60M -159.39% | -10.16M -137.27% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -43.32% | -16.79M -52.12% | -22.01M -69.84% | -22.58M -64.99% | -24.59M -68.90% | -25.16M -49.85% | -25.24M -14.70% | -26.54M -17.54% | -25.13M -2.17% | -21.97M +12.70% | -30.43M -20.56% | -24.31M +8.40% | -26.84M -6.80% | -26.35M -19.95% | -25.71M +15.52% | -26.25M -7.98% | -10.80M +59.76% | 112.93M +528.56% | -23.28M +9.44% | -38.00M -44.76% | -57.84M -435.58% | -6.19M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -3.01M -- | -3.32M -- | 8.24M -- | -5.74M -- | -7.82M -159.77% | -8.60M -159.39% | 22.16M +169.03% | -11.04M -92.25% | -12.96M -65.74% | -13.68M -59.04% | -14.56M -165.69% | -16.79M -52.12% | -22.01M -69.84% | -22.58M -64.99% | -24.59M -68.90% | -25.16M -49.85% | -25.24M -14.70% | -26.54M -17.54% | -25.13M -2.17% | -21.97M +12.70% | -30.43M -20.56% | -24.31M +8.40% | -26.84M -6.80% | -26.35M -19.95% | -25.71M +15.52% | -26.25M -7.98% | -10.80M +59.76% | 112.93M +528.56% | -23.28M +9.44% | -38.00M -44.76% | -57.84M -435.58% | -6.19M -- |
Basic EPS | -2.78 -- | -4.36 -- | -4.75 -- | -- -- | -6.89 -147.84% | -1.54 +64.68% | -0.26 +94.53% | -0.31 -- | -0.34 +95.07% | -0.39 +74.68% | -0.41 -57.69% | -0.4 -29.03% | -0.46 -35.29% | -0.6 -53.85% | -0.61 -48.78% | -0.66 -65.00% | -0.66 -43.48% | -0.63 -5.00% | -0.66 -8.20% | -0.65 +1.52% | -0.53 +19.70% | -0.69 -9.52% | -0.55 +16.67% | -0.59 +9.23% | -0.57 -7.55% | -0.46 +33.33% | -0.47 +14.55% | -0.19 +67.80% | 1.95 +442.11% | -0.4 +13.04% | -0.65 -38.30% | -0.98 -415.79% | -0.08 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.55 -- | -- -- | -0.57 -- | -0.46 -- | -0.47 +14.55% | -- -- | 1.95 +442.11% | -0.4 +13.04% | -0.65 -38.30% | -- -- | -- -- |
Diluted EPS | -2.78 -- | -4.36 -- | -4.75 -- | -- -- | -6.89 -147.84% | -1.54 +64.68% | -0.26 +94.53% | -- -- | -0.34 +95.07% | -0.39 +74.68% | -0.41 -57.69% | -- -- | -0.46 -35.29% | -0.6 -53.85% | -0.61 -48.78% | -- -- | -0.66 -43.48% | -0.63 -5.00% | -0.66 -8.20% | -- -- | -0.53 +19.70% | -0.69 -9.52% | -0.55 +16.67% | -- -- | -0.57 -7.55% | -0.46 +33.33% | -0.47 +14.55% | -- -- | 1.9 +433.33% | -0.4 +13.04% | -0.65 -38.30% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.55 -- | -- -- | -0.57 -- | -0.46 -- | -0.47 +14.55% | -- -- | 1.9 +433.33% | -0.4 +13.04% | -0.65 -38.30% | -- -- | -- -- |
You can ask Aime
What is Stoke Therapeutics's gross profit margin?What is the revenue and EPS growth rate for Stoke Therapeutics year over year?What factors drove the changes in Stoke Therapeutics's revenue and profit?Did Stoke Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Stoke Therapeutics’s earnings call?What is the market's earnings forecast for Stoke Therapeutics next quarter?What were the key takeaways from Stoke Therapeutics's earnings call?What does Stoke Therapeutics do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
